Intermountain announces participation in new study evaluating investigational multi-cancer early detection blood test. Intermountain Healthcare announced it will participate in the PATHFINDER Study, a prospective, multi-center study to evaluate the implementation of an investigational multi-cancer early detection blood test into clinical practice for the first time. The test uses single blood draw to identify multiple types of deadly cancer across stages I-IV.
IRMF grants inspire leading edge research projects. For the first quarter of 2020, Intermountain Research and Medical Foundation has announced approval of the three grants for innovative research projects. Denitza P. Blagev, MD, will look at E-cigarette, or Vaping, Associated Lung Injury (E-VALI), a new disease of unknown cause, treatment, and clinical outcomes. Meghan M. Cirulis, MD, Fellow, will explore the observable traits of the response of the lower right chamber of the heart in acute blockage of a lung artery (pulmonary embolism-PE). Manuel I. Rodriguez-Davalos, MD, FACS, is trying to develop models to let surgeons practice liver surgery through the creation of 3D-printed models of the liver.
Study finds phone app effectively identifies potentially fatal heart attacks with the near accuracy of a standard ECG. The American Heart Journal recently published findings for an international study which found that a smartphone app to monitor heart activity and determine if someone is having an ST-Elevation Myocardial Infarction (STEMI), a heart attack in which the artery is completely blocked, has nearly the same accuracy as a standard 12-lead electrocardiogram (ECG), which is used to diagnose heart attacks. This study was led by researchers from the Intermountain Medical Center Heart Institute.